JAK2 Fusion

CI-VAR-00001188Explore in graph →CIViC 571

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like1
PCM1::JAK2 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	3	accepted	EID7704 The PCM1-JAK2 fusion is typically associated with 'myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements', which is a specific disease entity according to WHO classification. However, i… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC	civic
Hematopoietic and Lymphoid Cell Neoplasm1
PCM1::JAK2 Fusion	(diagnostic)	Diagnostic	A	Supports Positive	5	accepted	EID1436 The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Myeloid Neoplasm1
PCM1::JAK2 Fusion OR BCR::JAK2 Fusion	Ruxolitinib	Predictive	B	Supports Sensitivity Response	2	submitted	EID11325 In this study, 18 patients with PCM1-JAK2 (n = 8), BCR-JAK2 (n = 1), and ETV6-ABL1 (n = 9) fusion genes were enrolled. RT-PCR was performed for confirmation of PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion… (full text at CIViC) PMID 32279331 · Schwaab et al., 2020 · Open in CIViC	civic